GLP-1 Receptor Agonists: Metabolic Effects and Their Role in Managing T2DM
Credit(s): 1.00 (60 min)
Sunday, September 11, 2022 7:00 - 8:00 PM ETWednesday, September 14, 2022 6:00 - 7:00 PM ETWednesday, November 2, 2022 12:15 - 1:15 PM CTMonday, January 26, 2023 7:00 - 8:00 PM CT
Physicians – AMA PRA Category 1 Credit(s) ™
Physicians – prescribed AAFP Credit(s)
Physicians/ABIM MOC – ABIM MOC Point(s)
Physician Assistants – AAPA Category 1 CME
Nurse Practitioners – contact hour(s) of continuing education
In T2DM there is a combination of reduced insulin production and secretion and insulin resistance. One cause of decreased insulin secretion is an impaired response to glucose-stimulated release of glucagon-like peptide 1 (GLP-1). Endogenous GLP-1 has multiple physiologic effects but is short-lived. GLP-1 receptor analogues (RAs) have a longer half-life, retain bioactivity, and have benefits beyond glycemic management, including mediating satiety; causing weight loss; and favorable cardiovascular, hepatic, and renal effects.
Based on the wide-ranging beneficial effects of GLP-1 RAs, the management of T2DM is no longer based on glucose control alone. The most recent ADA guidelines for T2DM provide guidance on drug- and patient-specific factors to consider when selecting an antihyperglycemic agent and therapeutic algorithms that center on a patient’s cardiovascular and renal profiles.
GLP-1 Receptor Agonists: Metabolic Effects and Their Role in Managing T2DM will inform clinicians about the pleiotropic effects of GLP-1 RAs, the demonstrated clinical efficacy of these agents for managing patients with T2DM and a variety of comorbid conditions, and guideline recommendations for incorporating GLP-1 RAs into management strategies for T2DM.
Jointly provided by the Potomac Center for Medical Education and Rockpointe
This program is supported by an educational grant from Novo Nordisk.
Clicking Start Activity indicates that you have reviewed the CME/CE information for this activity
Improving Cardiovascular Outcomes in T2DM: Personalizing Antihyperglycemic Therapy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.